Rain Therapeutics Inc. – NASDAQ:RAIN
Founder-led company
Rain Therapeutics stock price today
$3.1
+1.89
+156.2%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Rain Therapeutics stock price quarterly change
+14.15%
quarter
Rain Therapeutics stock price yearly change
-87.28%
year
Rain Therapeutics key metrics
Market Cap | 44.01M |
Enterprise value | 146.25M |
P/E | -2.59 |
EV/Sales | N/A |
EV/EBITDA | -1.93 |
Price/Sales | N/A |
Price/Book | 1.83 |
PEG ratio | 0.06 |
EPS | -2.03 |
Revenue | N/A |
EBITDA | -70.91M |
Income | -71.00M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRain Therapeutics stock price history
Rain Therapeutics stock forecast
Rain Therapeutics financial statements
| Dec 2022 | 0 | -22.67M | |
|---|---|---|---|
| Mar 2023 | 0 | -19.22M | |
| Jun 2023 | 0 | -22.06M | |
| Sep 2023 | 0 | -7.03M |
| 2025 | 0 | -23.57M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-03-14 | -0.29 | -0.7 |
|---|
| Dec 2022 | 135180000 | 22.14M | 16.38% |
|---|---|---|---|
| Mar 2023 | 114178000 | 19.62M | 17.18% |
| Jun 2023 | 91723000 | 18.43M | 20.1% |
| Sep 2023 | 82060000 | 14.54M | 17.72% |
| Dec 2022 | -13.29M | -17.19M | 52.60K |
|---|---|---|---|
| Mar 2023 | -21.83M | 3.51M | 466K |
| Jun 2023 | -23.62M | 19.58M | 12K |
| Sep 2023 | -6.99M | 4.23M | 0 |
Rain Therapeutics alternative data
| Aug 2023 | 63 |
|---|---|
| Sep 2023 | 63 |
| Oct 2023 | 63 |
| Nov 2023 | 63 |
| Dec 2023 | 63 |
| Jan 2024 | 63 |
| Feb 2024 | 63 |
| Apr 2024 | 63 |
| May 2024 | 63 |
| Jun 2024 | 63 |
| Jul 2024 | 63 |
Rain Therapeutics other data
7.81%
-73.00%
of RAIN is owned by hedge funds
27
-19
2.18M
-19.28M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 754948 | 995000 |
| Jun 2023 | 333325 | 0 |
| Oct 2023 | 284145 | 0 |
| Dec 2023 | 0 | 173973 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | TANG KEVIN C 10 percent owner | Common Stock | 40,132 | $1.21 | $48,560 | ||
Sale | TANG KEVIN C 10 percent owner | Common Stock | 109,435 | $1.2 | $131,322 | ||
Sale | TANG KEVIN C 10 percent owner | Common Stock | 24,406 | $1.21 | $29,531 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 84,145 | $0.99 | $83,304 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 47,486 | $0.99 | $47,011 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 52,514 | $0.98 | $51,464 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 25,188 | $0.98 | $24,684 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 74,812 | $0.97 | $72,568 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 92,984 | $1.09 | $101,353 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 240,341 | $1.12 | $269,182 |
| Quarter | Transcript |
|---|---|
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 13 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 9 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 12 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Avanish Vellanki M.B.A. (1975) Co-Founder, Chief Executive Officer & Chairman | $605,380 |
| Dr. Robert C. Doebele M.D., Ph.D. (1971) Co-Founder, Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer | $307,570 |
| Mr. Nelson D. Cabatuan (1978) Senior Vice President of Fin. & Admin. | $142,150 |
-
What's the price of Rain Therapeutics stock today?
One share of Rain Therapeutics stock can currently be purchased for approximately $3.1.
-
When is Rain Therapeutics's next earnings date?
Unfortunately, Rain Therapeutics's (RAIN) next earnings date is currently unknown.
-
Does Rain Therapeutics pay dividends?
No, Rain Therapeutics does not pay dividends.
-
How much money does Rain Therapeutics make?
Rain Therapeutics has a market capitalization of 44.01M. Rain Therapeutics made a loss 75.72M US dollars in net income (profit) last year or -$0.7 on an earnings per share basis.
-
What is Rain Therapeutics's stock symbol?
Rain Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "RAIN".
-
What is Rain Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rain Therapeutics?
Shares of Rain Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rain Therapeutics's key executives?
Rain Therapeutics's management team includes the following people:
- Mr. Avanish Vellanki M.B.A. Co-Founder, Chief Executive Officer & Chairman(age: 50, pay: $605,380)
- Dr. Robert C. Doebele M.D., Ph.D. Co-Founder, Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer(age: 54, pay: $307,570)
- Mr. Nelson D. Cabatuan Senior Vice President of Fin. & Admin.(age: 47, pay: $142,150)
-
Is Rain Therapeutics founder-led company?
Yes, Rain Therapeutics is a company led by its founders Mr. Avanish Vellanki M.B.A. and Dr. Robert C. Doebele M.D., Ph.D..
-
How many employees does Rain Therapeutics have?
As Jul 2024, Rain Therapeutics employs 63 workers.
-
When Rain Therapeutics went public?
Rain Therapeutics Inc. is publicly traded company for more then 4 years since IPO on 23 Apr 2021.
-
What is Rain Therapeutics's official website?
The official website for Rain Therapeutics is rainthera.com.
-
Where are Rain Therapeutics's headquarters?
Rain Therapeutics is headquartered at 8000 Jarvis Avenue, Newark, CA.
-
How can i contact Rain Therapeutics?
Rain Therapeutics's mailing address is 8000 Jarvis Avenue, Newark, CA and company can be reached via phone at +51 09535559.
Rain Therapeutics company profile:
Rain Therapeutics Inc.
rainthera.comExchange:
NASDAQ
Full time employees:
63
Industry:
Biotechnology
Sector:
Healthcare
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
8000 Jarvis Avenue
Newark, CA 94560
Newark, CA 94560
CIK: 0001724979
ISIN: US75082Q1058
CUSIP: 75082Q105
